Final clinical trials for Oxford University and AstraZeneca’s COVID-19 vaccine have been paused after a participant has reported an adverse reaction.
The vaccine has been tipped globally to be one of the first to become commercially available following successful phase one and two testing.
A spokesperson for AstraZeneca has described the halt in testing as a routine response to an unexplained illness.